prevail
therapeutics
announces
decisive
victory
arbitration
brought
alector
prevail
ceo
new
york
globe
newswire
prevail
therapeutics
nasdaq
prvl
biotechnology
company
developing
potentially
gene
therapies
patients
neurodegenerative
diseases
today
announced
decisive
victory
arbitration
proceeding
brought
alector
prevail
founder
chief
executive
officer
asa
abeliovich
arbitrator
rejected
alector
principal
claims
abeliovich
including
claims
alleging
misappropriation
misuse
trade
secrets
significantly
arbitrator
rejected
alector
claims
abeliovich
used
alector
trade
secrets
confidential
information
connection
work
behalf
prevail
well
alector
claim
rights
prevail
patents
patent
applications
prevail
party
arbitration
appreciate
arbitrator
thorough
independent
review
matter
decision
vindicates
abeliovich
rules
favor
significant
issues
said
francois
nader
chairman
prevail
positive
outcome
prevail
looking
forward
advancing
pipeline
benefit
pleased
decision
confirms
prevail
ownership
intellectual
property
said
abeliovich
team
continues
advance
pipeline
remains
committed
critical
mission
developing
novel
urgently
needed
therapies
patients
neurodegenerative
disorders
parkinson
disease
frontotemporal
relief
granted
alector
arbitrator
permission
seek
reimbursement
portion
alector
costs
fees
connection
certain
document
claims
alector
need
provide
sufficient
proof
amounts
prevail
therapeutics
prevail
clinical
stage
gene
therapy
company
leveraging
breakthroughs
human
genetics
goal
developing
commercializing
gene
therapies
patients
neurodegenerative
diseases
company
developing
patients
parkinson
disease
mutations
neuronopathic
gaucher
disease
ngd
patients
frontotemporal
dementia
grn
mutations
patients
certain
synucleinopathies
prevail
founded
asa
abeliovich
collaborative
effort
silverstein
foundation
parkinson
gba
orbimed
headquartered
new
york
ny
statements
related
prevail
statements
contained
press
release
regarding
matters
historical
facts
statements
within
meaning
private
securities
litigation
reform
act
amended
examples
statements
include
statements
concerning
amount
costs
legal
fees
prevail
may
required
reimburse
statements
subject
risks
uncertainties
actual
results
may
differ
materially
expressed
implied
statements
risks
uncertainties
include
among
others
prevail
novel
approach
gene
therapy
makes
difficult
predict
time
cost
potential
success
product
candidate
development
regulatory
approval
prevail
gene
therapy
programs
may
meet
safety
efficacy
levels
needed
support
ongoing
clinical
development
regulatory
approval
regulatory
landscape
gene
therapy
rigorous
complex
uncertain
subject
change
fact
gene
therapies
novel
complex
difficult
manufacture
risks
relating
impact
business
pandemic
similar
public
health
crises
risks
described
fully
prevail
filings
securities
exchange
commission
sec
including
risk
factors
section
company
quarterly
report
form
period
ended
june
filed
sec
august
documents
subsequently
filed
furnished
sec
statements
contained
press
release
speak
date
made
except
extent
required
law
prevail
undertakes
obligation
update
statements
reflect
events
occur
circumstances
exist
date
made
media
contact
gina
nugent
ten
bridge
communications
gina
investor
contact
investors
